InvestorsHub Logo
icon url

blue finch

08/21/21 4:26 PM

#326788 RE: falconer66a #326787

Thanks for continuing to post
Excellent summaries

Best of luck
icon url

FitzyP33

08/21/21 5:40 PM

#326793 RE: falconer66a #326787

What Anavex organic chemists? I don't see any on staff unless you mean Kaufman or Missling which is fine by me....the point is Anavex has so little staff and the way I interpreted your post is Anavex has many, many chemists. No way.

icon url

frrol

08/22/21 11:32 AM

#326840 RE: falconer66a #326787

No. Our two primary S1 agonists were not developed by "Anavex chemists" but by two different outside developers (we are licensees), and they are by no means the only two magically possible molecules for agonizing S1 safely and therapeutically. These "definitive" claims are definitively nonsense. There can be 1 other molecule, or 1,000 others.

And we don't even know if 3-71 is efficacious in human disease yet, so any proclamations about that molecule's unique effectiveness are false from the very start.

Also, the White Swan Fallacy that because you don't see a non-white swan that means they don't exist, that's nonsense, really poor reasoning, and fundamentally unscientific. Most folks trained in basic science know that, I suspect. (Btw we know of one non-white swan, a small company in clinical trials with a new S1 agonist for a CNS indication.)

FXS is a particularly exciting indication for us to pursue given its pathogenesis (effectively gene silencing) and the results with those KO models, which are pretty darn true to the actual condition (in mice). Looking forward to our clinical trial!